Johnson & Johnson has announced European approval for eligible multiple myeloma patients or caregivers to self-administer DARZALEX® from the fifth dose onwards.
Gilead Sciences and Kite have announced the reimbursement of two CAR T-cell therapies in Ireland for eligible adult patients with certain relapsed or refractory blood cancers.
Gilead Sciences and Kite have confirmed that Tecartus (brexucabtagene autoleucel), the first CAR T therapy for relapsed or refractory adult B-cell precursor acute lymphoblastic leukaemia, is now reimbursed in Ireland, offering a personalised treatment option supported by pivotal ZUMA-3 trial data.
Introduction: In the ever-evolving world of cancer care, staying informed is crucial The Irish Haematology Oncology Podcast is your go-to resource for clear, concise, and engaging discussions on the…
Background: Anticoagulants are frequently prescribed medications. In Ireland, direct oral anticoagulants are the anticoagulants of choice in most cases but vitamin K antagonists still have a vital role…
The Novus test, SepTec, analyses blood samples and diagnoses life-threatening bloodstream infections in just 15 minutes Deal brings to €7.4m the total funds raised by company to…
Background: Venous Thromboembolism (VTE) is a leading cause of maternal death in the developed world. 1 Although a rare event, occurring in approximately 1-2 per 1,000 pregnancies, 2…
Written by Dr Deirdre Lundy, Clinical Lead, Complex Menopause Service, NMH, Holles St Levels of female reproductive hormone will start to become less predictable and then drop; sometimes…
Authors: Dr Katie Liston and Dr Ciara O’Rafferty, Department of Haematology, Tallaght University Hospital, Dublin The epidemiology and relevance of Hospital-Acquired Thrombosis (HAT) Venous thromboembolism (VTE) is defined…
Written by Dr Stuart Macleod & Dr Barry Kevane, Department of Haematology, Mater Misericordiae University Hospital, Dublin Introduction Venous Thromboembolism (VTE) is a potentially devastating and yet frequently…
You’re all caught up.
